Effect of NR3C2 Genetic Polymorphisms on the Blood Pressure Response to Enalapril Treatment

• Brugts JJ , den Uil CA, Danser AH, Boersma E. The renin–angiotensin–aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology112(4) , 303–312 (2009).
   PubMed Web of Science ®Google Scholar
• Benetos A , CambienF, GautierS et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 28(6) , 1081–1084 (1996).
   PubMed Web of Science ®Google Scholar
• Ohmichi N , IwaiN, UchidaY, ShichiriG, NakamuraY, KinoshitaM. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens.10(8) , 951–955 (1997).
   PubMed Web of Science ®Google Scholar
• Brugts JJ , IsaacsA, de Maat MP et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J. Hypertens.29(3) , 509–519 (2011).
   PubMed Web of Science ®Google Scholar
• White PC . Disorders of aldosterone biosynthesis and action. N. Engl. J. Med.331(4) , 250–258(1994).
   PubMed Web of Science ®Google Scholar
• Yu HM , LinSG, LiuGZ, ZhangYQ, MaWJ, DengCY. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin. Pharmacol. Ther.79(6) , 581–589 (2006).
   PubMed Web of Science ®Google Scholar
• Yu H , LinS, ZhangY, LiuG. Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J. Hypertens.26(2) , 251–256 (2008).
   PubMed Web of Science ®Google Scholar
• Grossmann C , BenesicA, KrugAW et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 19(7) , 1697–1710 (2005).
   PubMedGoogle Scholar
• Sugiyama T , YoshimotoT, TsuchiyaK et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146(9) , 3900–3906 (2005).
   PubMed Web of Science ®Google Scholar
• Leopold JA , DamA, MaronBA et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13(2) , 189–197 (2007).
   PubMed Web of Science ®Google Scholar
• Silva PS , FontanaV, PaleiAC, SertorioJT, BiagiC, Tanus-SantosJE. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur. J. Clin. Pharmacol.67(4) , 365–370 (2011).
   PubMed Web of Science ®Google Scholar
• Hubert EL , TeissierR, Fernandes-RosaFL et al. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J. Am. Soc. Nephrol. 22(11) , 1997–2003 (2011).
   PubMed Web of Science ®Google Scholar
• Riepe FG , FinkeldeiJ, de Sanctis L et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J. Clin. Endocrinol. Metab.91(11) , 4552–4561 (2006).
   PubMed Web of Science ®Google Scholar
• Pujo L , FagartJ, GaryF et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum. Mutat. 28(1) , 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Fernandes-Rosa FL , HubertEL, FagartJ et al. Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1. J. Clin. Endocrinol. Metab. 96(3) , E519–E527 (2011).
   PubMed Web of Science ®Google Scholar
• Geller DS , FarhiA, PinkertonN et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289(5476) , 119–123 (2000).
   PubMed Web of Science ®Google Scholar
• DeRijk RH , WustS, MeijerOC et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J. Clin. Endocrinol. Metab. 91(12) , 5083–5089 (2006).
   PubMed Web of Science ®Google Scholar
• Nossent AY , HansenJL, DoggenC, QuaxPH, SheikhSP, RosendaalFR. SNPs in microRNA binding sites in 3´-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am. J. Hypertens.24(9) , 999–1006 (2011).
   PubMed Web of Science ®Google Scholar
• Arai K , NakagomiY, IketaniM et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum. Genet. 112(1) , 91–97 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez F , MansegoML, EscuderoJC, RedonJ, ChavesFJ. Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am. J. Hypertens.22(6) , 649–655 (2009).
   PubMed Web of Science ®Google Scholar
• van Leeuwen N , CaprioM, BlayaC et al. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 56(5) , 995–1002 (2010).
   PubMed Web of Science ®Google Scholar
• Galuppo P , BauersachsJ. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances. Eur. J. Clin. Invest.42(10) , 1112–1120 (2012).
   PubMed Web of Science ®Google Scholar
• Kortmann GL , ContiniV, BertuzziGP et al. The role of a mineralocorticoid receptor gene functional polymorphism in the symptom dimensions of persistent ADHD. Eur. Arch. Psychiatry Clin. Neurosci. 263(3) , 181–188 (2013).
   PubMed Web of Science ®Google Scholar
• Sia SK , ChiouHL, ChenSC, TsaiCF, YangSF, UengKC. Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population. Mol. Biol. Rep.40(5) , 3705–3711 (2013).
   PubMed Web of Science ®Google Scholar
• Arnett DK , DavisBR, FordCE et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111(25) , 3374–3383 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang X , LynchAI, DavisBR et al. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS ONE 7(3) , e34217 (2012).
   PubMed Web of Science ®Google Scholar
• Brugts JJ , de Maat MP, Boersma E et al. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther.23(2) , 171–181 (2009).
   PubMed Web of Science ®Google Scholar
• Brugts JJ , BoersmaE, SimoonsML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics11(8) , 1115–1126 (2010).
   PubMed Web of Science ®Google Scholar
• Silva PS , FontanaV, LuizonMR et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur. J. Clin. Pharmacol. 69(2) , 167–177 (2013).
   PubMed Web of Science ®Google Scholar
• Matayoshi T , KamideK, TakiuchiS et al. The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res. 27(11) , 821–833 (2004).
   PubMed Web of Science ®Google Scholar

▪ Website

• The database of Han Chinese in Beijing (CHB) in the HapMap Project. http://snp.cshl.org/cgi-perl/gbrowse/hapmap24_B36 (Accessed July2013)
   Google Scholar